A021602

Schema

1 Cycle = 28 Days



* Randomization will be done separately for the pancreatic NET and carcinoid tumor cohorts.

** Treatment is to continue until disease progression, unacceptable toxicity, or withdrawal of consent. Patients initially randomized to placebo who experience centrally confirmed progressive disease (PD) may elect to crossover to open-label cabozantinib; see Section 3.3 and Section 4.8. Patients will be followed for survival and progression every 12 weeks until progression or start of new anticancer therapy, and then for survival every 6 months until 8 years after registration or until death, whichever comes first.

NOTE: imaging scans must be submitted for real-time central review within 24 hours of local determination of PD; see Section 6.3.

Imaging after cessation of therapy may be performed at a non-registering institution. If the Group credited for enrollment is a non-Alliance Group, then other requirements from the credited Group may apply. All protocol conduct must be followed, and the registering institution is responsible for ensuring all data is reported per protocol.

Please see full protocol text for a complete description of the eligibility criteria (Section 3.0) and treatment plan (Section 7.0).